Get the Stockscreener App
0.86
2.00%
-0.0175
Imunon Inc stock is traded at $0.86, with a volume of 15,672.
It is down -2.00% in the last 24 hours and down -21.10% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$0.8775
Open:
$0.86
24h Volume:
15,672
Relative Volume:
0.13
Market Cap:
$12.99M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-0.455
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
-3.21%
1M Performance:
-21.10%
6M Performance:
-10.97%
1Y Performance:
-40.28%
1-Day Range:
$0.8501
$0.869
1-Week Range:
$0.832
$0.9079
52-Week Range:
$0.64
$3.65
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
0.86 | 12.99M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Stock (IMNN) Latest News
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - ADVFN
Imunon, Inc. (NASDAQ:IMNN) Sees Significant Growth in Short Interest - Defense World
Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO - TipRanks
IMUNON (IMNN) Reveals Promising Survival Data for Advanced Ovari - GuruFocus
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | IMNN Stock News - GuruFocus
IMUNON, Inc. Announces Presentation of Promising Overall Survival Data from Phase 2 OVATION 2 Study for Advanced Ovarian Cancer and Initiation of Phase 3 Trial Sites for IMNN-001 - Nasdaq
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewswire
First Effective IL-12 Immunotherapy Shows Survival Benefits in Advanced Ovarian CancerASCO 2025 Preview - Stock Titan
Imunon (NASDAQ:IMNN) Trading Down 1.9% – Time to Sell? - Defense World
Celsion Corporation Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board - marketscreener.com
Imunon (IMNN) Files to Sell 10 Million Shares, Warrants - GuruFocus
DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks
Stacy Lindborg, PhD's Profile Page - Technology Networks
Companies To Watch: Imunon - Life Science Leader
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Smartkarma
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research
Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo
Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World
IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks
IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire
Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan
IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com
Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks
Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025 - Smartkarma
Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance
IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks
Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com
Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView
IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView
IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire
IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance
Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks
IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan
Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily
The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times
IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter
IMNNImunon Inc Latest Stock News & Market Updates - Stock Titan
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):